Loading clinical trials...

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. | Clinical Trials | Clareo Health

UNKNOWNEARLY_PHASE1

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

The Safety and Efficacy Study of Autologous Tumor-infiltrating Lymphocyte (TILs) Therapy Combined With Conventional Chemotherapy for Patients With Advanced Stage of Glioblastoma Multiforme.

NCT05333588•Hebei Senlang Biotechnology Inc., Ltd.

View on ClinicalTrials.gov

Summary

The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age: 18 to 80 years old;
•2. Has at least one measurable tumor foci;
•3. ECOG score range : 0-2;
•4. Expected survival time: ≥ 3 months;
•5. All screening labs should be performed 7 days prior to registration.The laboratory results need to meet below criteria:
•* Absolute white blood cell counts (WBC) ≥ 3.0×10\^9/L；
•* Platelet count (PLT) ≥ 100×10\^9/L；
•* Hematological Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L；
•* Hemoglobin (HGB) ≥ 90g/L;
•* Albumin (absolute) ≥ 2.8g/dL;
+8 more criteria

Exclusion Criteria

•1. Has systemic active infection and requiring treatment;
•2. Has severe physical or mental illness;
•3. Has active rheumatic disease;
•4. Has any kinds of organ transplantation;
•5. Being pregnant or lactating;
•6. Enrolled in other clinical trials within 4 weeks prior to registration;
•7. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C;
•8. Other conditions that the researcher considered to be excluded;
•9. Has taken blow treatment before enrollment:
•* Received systemic immunosuppressive treatments, aside from corticosteroids within 14 days of treatment;
+1 more criteria

Locations (1)

The Second Hospital of HeBei Medical University

Shijiazhuang, Hebei, China

Key Dates

Start Date

February 15, 2022

Primary Completion Date

February 15, 2024

Completion Date

February 15, 2025

Last Updated

April 19, 2022

Enrollment

ESTIMATED participants

Conditions

Glioblastoma Multiforme, Adult

Interventions

Tumor Infiltrating Lymphocytes (TIL)

BIOLOGICAL

Contacts

Na Kuang

CONTACT

+8618630160116 kuangna@senlangbio.com

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

NCT07100730

Neoplastic DiseaseGlioblastoma+4 more

View study

RECRUITINGPHASE2

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

NCT05052957

Glioblastoma MultiformeGlioblastoma Multiforme, Adult+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 19, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Inclusion Criteria

Exclusion Criteria

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

Patient's Derived Organoids for Drug Screening in Glioblastoma

Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy